XT
ORMP icon

XTX Topco’s Oramed Pharmaceuticals ORMP Stock Holding History

XTX Topco’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
49,923
+27,235
+120% +$108K ﹤0.01% 3102
2026
Q1 		$77.1K Sell
22,688
-15,494
-41% -$52.6K ﹤0.01% 3185
2025
Q4 		$109K Buy
38,182
+14,297
+60% +$36.9K ﹤0.01% 2614
2025
Q3 		$63.1K Buy
+23,885
New +$52.8K ﹤0.01% 2124
2024
Q4 		– Sell
-24,716
Closed -$60.3K – 2757
2024
Q3 		$60.3K Buy
24,716
+9,242
+60% +$22.5K ﹤0.01% 1667
2024
Q2 		$39.8K Buy
+15,474
New +$36.8K ﹤0.01% 1533
2024
Q1 		– Sell
-17,325
Closed -$40K – 2184
2023
Q4 		$40K Buy
+17,325
New +$37K 0.01% 1274
2023
Q2 		– Sell
-151,620
Closed -$331K – 1718
2023
Q1 		$331K Buy
151,620
+94,537
+166% +$300K 0.07% 579
2022
Q4 		$687K Buy
+57,083
New +$444K 0.15% 179
2022
Q3 		– Sell
-18,174
Closed -$83K – 1309
2022
Q2 		$83K Buy
+18,174
New +$97.1K 0.03% 687
2022
Q1 		– Sell
-10,556
Closed -$151K – 887
2021
Q4 		$151K Buy
+10,556
New +$221K 0.09% 409

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco's ORMP Position: Q2 2026 in Review

XTX Topco increased its Oramed Pharmaceuticals (ORMP) stake by 120% in Q2 2026, buying an estimated $108K and bringing the position to 49,923 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #3102.

XTX Topco first reported a position in ORMP in Q4 2021 and has held it in 11 quarters since. The position peaked at $687K in Q4 2022. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • XTX Topco held 49,923 shares of Oramed Pharmaceuticals worth $240K as of Q2 2026.
  • XTX Topco bought 27,235 Oramed Pharmaceuticals shares in Q2 2026, an estimated $108K.
  • Oramed Pharmaceuticals made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3102 holding.
  • XTX Topco first reported a position in Oramed Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
  • XTX Topco's Oramed Pharmaceuticals position peaked at $687K in Q4 2022.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.